ArticleMolecular therapy oncolytics2022

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Emily A Bates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.